These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26056958)

  • 41. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
    Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
    Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Usefulness of Levosimendan in patients with ventricular dysfunction before surgery].
    Bauk L; López OF; Miranda GS; Abdala GG; Mora EL; de la Reguera GF
    Arch Cardiol Mex; 2004; 74(4):295-300. PubMed ID: 15709507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
    J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
    Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
    Avgeropoulou C; Andreadou I; Markantonis-Kyroudis S; Demopoulou M; Missovoulos P; Androulakis A; Kallikazaros I
    Eur J Heart Fail; 2005 Aug; 7(5):882-7. PubMed ID: 15921958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experiences of levosimendan as an inotropic agent in conjunction with passive containment surgery.
    Bredin F; Franco-Cereceda A
    Scand Cardiovasc J; 2007 Jun; 41(3):197-200. PubMed ID: 17487771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
    Lilleberg J; Ylönen V; Lehtonen L; Toivonen L
    Scand Cardiovasc J; 2004 May; 38(2):80-4. PubMed ID: 15204232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial.
    Momeni M; Rubay J; Matta A; Rennotte MT; Veyckemans F; Poncelet AJ; Clement de Clety S; Anslot C; Joomye R; Detaille T
    J Cardiothorac Vasc Anesth; 2011 Jun; 25(3):419-24. PubMed ID: 20829069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery.
    Lomivorotov VV; Cherniavskiy AM; Boboshko VA; Kornilov IA; Lomivorotov VN; Karaskov AM
    Asian Cardiovasc Thorac Ann; 2011 Apr; 19(2):154-9. PubMed ID: 21471262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levosimendan--an inoprotective drug or much ado about nothing?
    Lehmann A; Radke J; Sack FU
    Crit Care Med; 2011 Oct; 39(10):2365-6. PubMed ID: 21926495
    [No Abstract]   [Full Text] [Related]  

  • 56. Levosimendan for low cardiac output: a pediatric experience.
    Egan JR; Clarke AJ; Williams S; Cole AD; Ayer J; Jacobe S; Chard RB; Winlaw DS
    J Intensive Care Med; 2006; 21(3):183-7. PubMed ID: 16672640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do levosimendan have an adverse effect on platelet function?
    Kaptan K; Beyan C; Ifran A
    Int J Cardiol; 2010 Oct; 144(3):414-5. PubMed ID: 19327852
    [No Abstract]   [Full Text] [Related]  

  • 59. Levosimendan and cardiac surgery.
    De Santis V; Vitale D; Tritapepe L
    J Cardiothorac Vasc Anesth; 2010 Feb; 24(1):210. PubMed ID: 19264513
    [No Abstract]   [Full Text] [Related]  

  • 60. Levosimendan in acute and chronic right ventricle failure.
    Yontar OC; Yilmaz MB; Yalta K
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):118-9. PubMed ID: 19961440
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.